Patent number: 8324401
Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A1QA2-; Q is a bond, —C(?O)—, —OC(O)—, —C(?O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(?O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.
Type:
Grant
Filed:
August 18, 2009
Date of Patent:
December 4, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jingwu Duan, Bin Jiang
Publication number: 20100264368
Abstract: Liquid Crystal Molecules Comprising Hydroazulene Structures Compounds of formula (I); R1i-A1i-(Z2i-A2i)m-(Z3i-A3i)n-(Z4i-A4i)o-R2i (i) wherein at least one of the divalent groups Ai is derived from at least partially hydrogenated azulene, R1i and R2i being hydrogen, an optionally substituted alkyl or alkylene residue, R2i also standing for —CN, —N?C?S, —F, —Cl, —SF5, —CF3, —CHF2, CH2F—O—CF3, —O—CHF2, —O—CH2F, —O—CF2—CF2H, or —O—C2F5, A1i, A2i, A3i and A4i being partially or completely hydrogenated 2,6-azulene, trans-1,4-cyclohexylene, 1,4-cyclohexenylene, 1,4-phenylene, 2-fluoro-1,4-phenylene, 3-fluoro-14-phenylene, 2,3- and 2,6-difluoro-1,4-phenylene, and 3,5-difluoro-1,4-phenylene, pyrimidine-2,5-diyl, and 1,4-dioxane-2,5-diyl, Z1i, Z2i, Z3i and Z4i being a single bond, —CH2—CH2—, —CF2—CF2—, an ester bond —CO—O—, trans and —CF2—O—, m, n and 0 being independently 0, 1, or 2, liquid crystal media comprising these compounds and liquid crystal displays made with mixtures comprising the novel compounds.
Type:
Application
Filed:
June 19, 2006
Publication date:
October 21, 2010
Applicant:
TETRAGON-CHEMIE AG
Inventors:
Ludwig Pohl, Henning Hopf, Zakir Hussain
Publication number: 20100222338
Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
Type:
Application
Filed:
May 13, 2010
Publication date:
September 2, 2010
Inventors:
Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig E. Masse, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Holger Monenschein, Thomas Nguyen